Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
出版年份 2020 全文链接
标题
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
作者
关键词
-
出版物
Nature Reviews Nephrology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-11-21
DOI
10.1038/s41581-020-00367-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Innate immunity in diabetic kidney disease
- (2020) Sydney C. W. Tang et al. Nature Reviews Nephrology
- GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
- (2020) Matthew P. Gilbert et al. Frontiers in Endocrinology
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
- (2019) Radica Z. Alicic et al. DIABETES
- Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
- (2019) Carolyn F. Deacon Frontiers in Endocrinology
- DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
- (2019) Seung Jung Kim et al. BMC Nephrology
- Mechanisms of GLP-1 receptor–independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy
- (2019) Ahmed A. Hasan et al. KIDNEY INTERNATIONAL
- Burden, access, and disparities in kidney disease
- (2019) Deidra C. Crews et al. KIDNEY INTERNATIONAL
- US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2019) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial
- (2019) M.H.A. Muskiet et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide attenuates pre-established atherosclerosis in apolipoprotein E deficient mice via regulation of immune cell phenotypes and pro-inflammatory mediators
- (2019) Robyn Bruen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation
- (2019) Foteini Moschovaki Filippidou et al. AMERICAN JOURNAL OF PATHOLOGY
- Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression
- (2019) Ying Fan et al. DIABETES
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
- (2019) M. Angelyn Bethel et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen
- (2019) Liying Zhu et al. BIOMEDICINE & PHARMACOTHERAPY
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study
- (2019) Helga Ellingsgaard et al. DIABETOLOGIA
- Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
- (2018) Katherine G. Garlo et al. Clinical Journal of the American Society of Nephrology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk
- (2018) Benjamin M. Scirica et al. JAMA Cardiology
- Glucagon-Like Peptide-1 and its Cleavage Products are Renoprotective in Murine Diabetic Nephropathy
- (2018) Moellmann Julia et al. DIABETES
- Global trends in diabetes complications: a review of current evidence
- (2018) Jessica L. Harding et al. DIABETOLOGIA
- Co-storage and release of insulin-like peptide-5, glucagon-like peptide-1 and peptideYY from murine and human colonic enteroendocrine cells
- (2018) Lawrence J. Billing et al. Molecular Metabolism
- Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food
- (2018) Marie K. Holt et al. DIABETES
- GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
- (2018) Yanqing Zhang et al. DIABETES
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression
- (2017) Karishma Rahman et al. JOURNAL OF CLINICAL INVESTIGATION
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- (2017) Mohsen Mazidi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
- (2017) Ahmed A Hasan et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Tissue-Resident Lymphocytes in the Kidney
- (2017) Jan-Eric Turner et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
- (2017) Adeera Levin et al. LANCET
- Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity
- (2017) J J Worthington et al. Mucosal Immunology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
- (2016) Corinna Lebherz et al. Cardiovascular Diabetology
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
- (2016) C. Klemann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects
- (2016) Meena Shah et al. EUROPEAN JOURNAL OF NUTRITION
- Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells
- (2016) Rune Ehrenreich Kuhre et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes
- (2016) Muralikrishna Gangadharan Komala et al. NEPHROLOGY
- Diabetes and Cause-Specific Mortality in Mexico City
- (2016) Jesus Alegre-Díaz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
- (2016) Łukasz Bułdak et al. Pharmacological Reports
- Synthetic small molecule GLP-1 secretagogues prepared by means of a three-component indole annulation strategy
- (2016) Oleg G. Chepurny et al. Scientific Reports
- Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
- (2016) Nathan R. Hill et al. PLoS One
- Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors
- (2015) Lucia Cea Soriano et al. Cardiovascular Diabetology
- Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
- (2015) Xiao-Wu Chen et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice
- (2015) Serap Sancar-Bas et al. GROWTH FACTORS
- Worldwide access to treatment for end-stage kidney disease: a systematic review
- (2015) Thaminda Liyanage et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
- (2014) Rune E. Kuhre et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Structure of Class B GPCRs: new horizons for drug discovery
- (2014) Andrea Bortolato et al. BRITISH JOURNAL OF PHARMACOLOGY
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering
- (2014) F. Kahles et al. DIABETES
- Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
- (2014) Antonio Ceriello et al. DIABETES CARE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Acute effects of pistachio consumption on glucose and insulin, satiety hormones and endothelial function in the metabolic syndrome
- (2014) C W C Kendall et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Serum amyloid A and inflammation in diabetic kidney disease and podocytes
- (2014) Robert J Anderberg et al. LABORATORY INVESTIGATION
- Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
- (2014) Catarina Marques et al. MEDIATORS OF INFLAMMATION
- Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes
- (2014) André J. Tremblay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
- (2014) Jennifer M. Trujillo et al. PHARMACOTHERAPY
- Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe−/− mice
- (2013) Mathias Burgmaier et al. ATHEROSCLEROSIS
- Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
- (2013) Ryo Kodera et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets
- (2013) Elin Hall et al. BMC Medical Genetics
- Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
- (2013) A. Ceriello et al. DIABETES CARE
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
- (2013) Andrew E. Hogan et al. DIABETOLOGIA
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat
- (2013) Hua Yang et al. JOURNAL OF SURGICAL RESEARCH
- Protection of Glucagon-Like Peptide-1 in Cisplatin-Induced Renal Injury Elucidates Gut-Kidney Connection
- (2013) D. Katagiri et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
- (2013) Yen-Ta Chen et al. Journal of Translational Medicine
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
- (2013) Lan He et al. Journal of Diabetes Investigation
- DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes
- (2013) Annayya Aroor et al. CardioRenal Medicine
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Opportunities for functional selectivity in GPCR antibodies
- (2012) David R. Webb et al. BIOCHEMICAL PHARMACOLOGY
- Risks of Subsequent Hospitalization and Death in Patients with Kidney Disease
- (2012) K. B. Daratha et al. Clinical Journal of the American Society of Nephrology
- Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
- (2012) M. S. Fineman et al. DIABETES OBESITY & METABOLISM
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats
- (2012) Atul Sureshrao Akarte et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells
- (2012) Edwin K. Jackson et al. HYPERTENSION
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- The gut endocrine system as a coordinator of postprandial nutrient homoeostasis
- (2012) Fiona M. Gribble PROCEEDINGS OF THE NUTRITION SOCIETY
- The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
- (2011) Ho-Sang Moon et al. ARCHIVES OF PHARMACAL RESEARCH
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2
- (2011) G. Tolhurst et al. DIABETES
- Effect of Exenatide on Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus
- (2011) Jin-dan Wu et al. Diabetes Technology & Therapeutics
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
- (2010) I. Hadjiyanni et al. DIABETOLOGIA
- Reversal of New-Onset Diabetes through Modulating Inflammation and Stimulating β-Cell Replication in Nonobese Diabetic Mice by a Dipeptidyl Peptidase IV Inhibitor
- (2010) Lei Tian et al. ENDOCRINOLOGY
- Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
- (2009) Bo Ahrén BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions
- (2009) Nadine Frerker et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
- (2009) E. Matteucci et al. CURRENT MEDICINAL CHEMISTRY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- How reliable are G-protein-coupled receptor antibodies?
- (2009) Martin C. Michel et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Glucose Sensing in L Cells: A Primary Cell Study
- (2008) Frank Reimann et al. Cell Metabolism
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
- (2008) Kei Ohnuma et al. TRENDS IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search